Objective The number of radiomics studies in gastroenteropancreatic neuroendocrine tumours
(GEP-NETs) is rapidly increasing. This systematic review aims to provide an overview of …

Introduction Somatostatin receptor imaging with PET is the standard of care for patients with
a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues …

Background Response after peptide receptor radionuclide therapy (PRRT) can be
evaluated using anatomical imaging (CT/MRI), somatostatin receptor imaging ([ 68 Ga]Ga-DOTA-…

Background Most neuroendocrine tumours (NETs) metastasize to the liver, lymph nodes and,
although less frequently, to the bone. The heart is a rare localization for NET metastases. …

Purpose To compare the predictive value of new immunotherapy-specific fluorine-18-labeled
glucose Positron Emission Tomography/Computed Tomography ([ 18 F]FDG PET/CT) …

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with
neuroendocrine neoplasms. The aim of this study was to identify clinical and treatment …

The aim of this study was to associate and predict B-rapidly accelerated fibrosarcoma valine
600 (BRAFV600) mutation status with both conventional and radiomics 18 F-FDG PET/CT …

Aim The aim of this study was to evaluate the clinical utility of SPECT/CT (imaging of uptake
in tumor lesions and additional findings) and the additional value of planar imaging in order …

… Veerman, Hinke Siebinga, and Else Aalbersberg. The first draft of the manuscript was
written by Chayenne Veerman and Else Aalbersberg and all authors commented on previous …

Aims In vivo biodistribution imaging of platinum-based compounds may allow better patient
selection for treatment with chemo(radio)therapy. Radiolabeling with Platinum-195m ( 195m …